TelomeresPhase 1NCT04048044
EFFECTS OF RejuvaMatrix ™ ON TELOMERES
A Phase 1 study testing Exposure to GHz electromagnetic energy (RejuvaMatrix) in people with Telomeres, run by Holos Institutes of Health, Inc.
Trial summary
Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Telomeres
- What is being tested?
- Exposure to GHz electromagnetic energy (RejuvaMatrix)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Jan 2009to Dec 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- -
Who cannot join
- Implanted electronic device
- Major, debilitating disease
- Person living with an individual who has an implanted device
- Person who is or could become pregnant
About this study
Official title: THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES
Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate
Read the detailed description
Individuals who are post menopausal and who do not have an implanted electronic device, such as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on top of the regular mattress. Participants are provided with a Tesla coil to be attached to a copper wire coming from the copper screen. They will also be provided with a timer so that they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep.
Telomeres will be measured at the end of each year for 5 years.
- Conditions
- Telomeres
- Being tested
- Exposure to GHz electromagnetic energy (RejuvaMatrix)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exposure to GHz electromagnetic energy (RejuvaMatrix)Device
75 decibels of 54 to 78 GHz daily for 60 minutes
| Study group | Role | What they receive |
|---|---|---|
| Telomere length, GigaHz exposure | Active comparator | Measurement of white blood cell telomeres before and yearly for 5 years Receives: Device: Exposure to GHz electromagnetic energy (RejuvaMatrix) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of telomeres after 5 years compared with baseline
Measured: 5 years
Secondary outcomes (1)
Total Symptom Index
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2019
- Study startJan 2009
- Primary completionDec 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TelomeresStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Holos Institutes of Health, Inc
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, C. Norman Shealy, Holos Institutes of Health, Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04048044
- Sponsor's protocol ID
- HIH RM
- Status last verified
- May 2012
- First submitted
- 10 May 2012
- Last updated
- 7 Aug 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES
- ClinicalTrials.gov ID
- NCT04048044
- Acronym / sponsor ID
- HIH RM
- Conditions
- Telomeres
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Holos Institutes of Health, IncUniversity, hospital or other
- Study start
- Jan 2009 (actual)
- Primary completion
- Dec 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 7 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate
Detailed description
Individuals who are post menopausal and who do not have an implanted electronic device, such as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on top of the regular mattress. Participants are provided with a Tesla coil to be attached to a copper wire coming from the copper screen. They will also be provided with a timer so that they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep.
Telomeres will be measured at the end of each year for 5 years.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Telomere length, GigaHz exposure | Active comparator | Device: Exposure to GHz electromagnetic energy (RejuvaMatrix)Measurement of white blood cell telomeres before and yearly for 5 years |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (4 listed)
- Implanted electronic device
- Major, debilitating disease
- Person living with an individual who has an implanted device
- Person who is or could become pregnant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exposure to GHz electromagnetic energy (RejuvaMatrix)75 decibels of 54 to 78 GHz daily for 60 minutes | Device | Telomere length, GigaHz exposure |
Primary outcome
Length of telomeres after 5 years compared with baseline
Time frame: 5 years
1 secondary outcome
Total Symptom Index
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2019.
Related trials for Telomeres
RecruitingObservational study
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
Severe Aplastic Anemia, Telomere Biology Disorders
RecruitingObservational study
Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data
Inherited Bone Marrow Failure Syndrome, Fanconi Anemia
Enrolling by invitationObservational study
Telomeres Length in Israeli Fibrotic ILD Patients
Pulmonary Fibrosis
RecruitingObservational study
Socio-cognitive and Biological Responses to Maltreatment
Bipolar 1 Disorder, Control Subjects
RecruitingPhase 1
Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)
Dyskeratosis Congenita, Telomere Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Exposure to GHz electromagnetic energy (RejuvaMatrix) in people with Telomeres, run by Holos Institutes of Health, Inc.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of telomeres after 5 years compared with baseline (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2019.